Excelsyn expands US presence
With the aim of increasing the US share of its business to 33% by 2011, UK-based pharma and biotech services group Excelsyn has appointed Peter Chinigo to lead the business development drive in the US.
With the aim of increasing the US share of its business to 33% by 2011, UK-based pharma and biotech services group Excelsyn has appointed Peter Chinigo to lead the business development drive in the US.
Based in Michigan, he most recently served in business development for DSM’s emerging pharma division. With a Chemistry BSc and an MBA, and has previous experience with Pfizer and MIC Speciality Chemicals.
Chinigo will be supported by consultant Jim Bruno who brings three decades of experience in the US pharma and fine chemicals marketplace.
Excelsyn has now completed the initial phase of a three-year expansion and upgrade programme at its Holywell facility in North Wales.
Additional capabilities include Fauske adiabetic and TSU calorimetry equipment, enabling the company to conduct stability testing in-house, and laboratory hydrogenation capability with a bench scale 120 bar autoclave and a 3-litre, 5 bar autoclave.
The full programme will include a new API finishing suite, reactor train alignment and increased product isolation capacity.
Excelsyn is also currently undergoing voluntary auditing with the aim of gaining an MHRA licence to complement its FDA audit.